{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:53:12Z","timestamp":1793641992886,"version":"4.5.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-023-00937-0","type":"journal-article","created":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T22:01:33Z","timestamp":1699221693000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-9595","authenticated-orcid":false,"suffix":"Jr","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"McCaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1880-7094","authenticated-orcid":false,"given":"Andrew J.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurbakhash","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,6]]},"reference":[{"key":"937_CR1","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311\u201320.","journal-title":"N Engl J Med"},{"key":"937_CR2","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach JP, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136:936\u201345.","journal-title":"Blood."},{"key":"937_CR3","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387:132\u201347.","journal-title":"N Engl J Med"},{"key":"937_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0311-8","volume":"10","author":"BGM Durie","year":"2020","unstructured":"Durie BGM, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020;10:53.","journal-title":"Blood Cancer J"},{"key":"937_CR5","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","volume":"21","author":"S Kumar","year":"2020","unstructured":"Kumar S, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21:1317\u201330.","journal-title":"Lancet Oncol"},{"key":"937_CR6","doi-asserted-by":"publisher","first-page":"e0172996","DOI":"10.1371\/journal.pone.0172996","volume":"12","author":"S Sidana","year":"2017","unstructured":"Sidana S, Narkhede M, Elson P, Hastings D, Faiman B, Valent J, et al. Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis. PLoS ONE. 2017;12:e0172996.","journal-title":"PLoS ONE"},{"key":"937_CR7","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/10428194.2019.1675881","volume":"61","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, San-Miguel J, Goldschmidt H, Sonneveld P, Dimopoulos MA, Heeg B, et al. The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison. Leuk Lymphoma. 2020;61:680\u201390.","journal-title":"Leuk Lymphoma"},{"key":"937_CR8","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/ajh.26074","volume":"96","author":"J Cook","year":"2021","unstructured":"Cook J, Johnson I, Higgins A, Sidana S, Warsame R, Gonsalves W, et al. Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. Am J Hematol. 2021;96:330\u20137.","journal-title":"Am J Hematol"},{"key":"937_CR9","doi-asserted-by":"crossref","first-page":"544.","DOI":"10.1182\/blood-2023-178950","volume":"141","author":"FW Hoff","year":"2023","unstructured":"Hoff FW, Banerjee R, Khan AM, McCaughan GJ, Wang X, Roose J, et al. Retrospective observational study on real-world bortezomib prescribing patterns and outcomes in newly diagnosed multiple myeloma. Blood. 2023;141:544.","journal-title":"Blood"},{"key":"937_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/01947648.2014.913460","volume":"35","author":"C Taylor","year":"2014","unstructured":"Taylor C. The use of clinical practice guidelines in determining standard of care. J Leg Med. 2014;35:273\u201390.","journal-title":"J Leg Med"},{"key":"937_CR11","first-page":"109","volume":"12","author":"P Moffett","year":"2011","unstructured":"Moffett P, Moore G. The standard of care: legal history and definitions: the bad and good news. West J Emerg Med. 2011;12:109\u201312.","journal-title":"West J Emerg Med"},{"key":"937_CR12","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3324\/haematol.2015.124347","volume":"100","author":"M Merz","year":"2015","unstructured":"Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, et al. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Haematologica. 2015;100:964\u20139.","journal-title":"Haematologica."},{"key":"937_CR13","unstructured":"World Bank. World Bank Country and Lending Groups. World Bank;2023. [Cited 2023 Oct 24]. Available from: https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519."},{"key":"937_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00806-w","volume":"13","author":"N Leung","year":"2023","unstructured":"Leung N, Rajkumar SV. Multiple myeloma with acute light chain cast nephropathy. Blood Cancer J. 2023;13:46.","journal-title":"Blood Cancer J"},{"key":"937_CR15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/bjh.18295","volume":"199","author":"GJ McCaughan","year":"2022","unstructured":"McCaughan GJ, Gandolfi S, Moore JJ, Richardson PG. Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review. Br J Haematol. 2022;199:190\u2013204.","journal-title":"Br J Haematol"},{"key":"937_CR16","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378:518\u201328.","journal-title":"N Engl J Med"},{"key":"937_CR17","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","volume":"396","author":"S Grosicki","year":"2020","unstructured":"Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020;396:1563\u201373.","journal-title":"Lancet."},{"key":"937_CR18","unstructured":"Food and Drug Administration. Docket FDA-2006-D-0031. Informed Consent: Draft Guidance for IRBs, Clinical Investigators, and Sponsors. Food and Drug Administration;2023 [Cited 2023 Oct 24]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/informed-consent#_ftn14."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00937-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00937-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00937-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T04:21:32Z","timestamp":1703478092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00937-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,6]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["937"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00937-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,6]]},"assertion":[{"value":"24 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RB: Consulting: BMS, Caribou Biosciences, Genentech, Janssen, Pfizer, Sanofi, SparkCures; Research: Pack Health. GK: Consulting: BMS, Arcellx, Sanofi, Janssen, Pfizer, Kedrion; Research: BMS, Janssen, Abbvie. BW: Consulting: Sanofi, EMD Sorono, AstraZeneca, Janssen, BMS. LDA: Consulting: Janssen, BMS\/Celgene, Amgen, GSK, AbbVie, Beigene, Cellectar, Sanofi, Prothena. GM: Consulting: BMS, Janssen. NM: No interests to disclose. AJC: Consulting: BMS, Adaptive; Research: Adaptive Biotechnologies, Harpoon, Nektar, BMS, Janssen, Sanofi, AbbVie. SVR: No interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"162"}}